Lumea
James Thackeray is the Chief Commercial Officer at LUMEA since December 2017. With a background in sales and marketing, James has held various roles in companies like Leavitt Medical, Genomic Health, Clarient inc, Genzyme, and Genzyme Genetics. He holds a Master's Degree in Business Administration and Management from the University of Utah.
Lumea
Lumea is reshaping the pathology landscape with innovative technology solutions that elevate and enhance the entire pathology ecosystem. Since its founding in 2013, Lumea has pioneered one of the first software platforms of its kind, offering a comprehensive suite of products, including proprietary specimen-handling consumables, a digitally-enabled Laboratory Information System (LIS), and a premier IMS/Viewer. Lumea’s unique approach to digital pathology not only increases cancer detection rates but also delivers a substantial return on investment in a cost-sensitive environment and ultimately sets a higher standard of patient care in cancer diagnostics. With over 1.5 million digital diagnoses, Lumea ranks among the top 5 digital pathology platforms for clinical use in the United States. For further insights into the transformative benefits of Lumea technology, visit lumeadigital.com.